TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A randomized controlled trial led by the University of Surrey found that participants taking NOVOS Core for six months had improved endothelial function, arterial stiffness and systolic blood pressure compared with a placebo group. The 61-person study measured health markers, not cardiovascular events, and researchers say larger studies are needed to determine whether the changes lead to lasting health benefits.
A randomized controlled trial led by the University of Surrey found that adults taking the multi-component supplement NOVOS Core for six months had improved measures of endothelial function, arterial stiffness and systolic blood pressure compared with participants given a placebo. The 61-person study assessed cardiovascular health markers rather than heart attacks, strokes or other clinical outcomes, so it does not establish that the supplement prevents cardiovascular disease.
The trial included 61 participants: 33 were assigned to take NOVOS Core once daily and 28 to take a placebo. Researchers assessed vascular measures over the six-month study. They also reported an improvement in blood vessel function and a difference in systolic blood pressure one hour after the first dose; those measures were largely unchanged in the control group.
At six months, the adjusted difference between groups in systolic blood pressure was 6.1 mmHg in favor of the supplement group. Pulse wave velocity, a measure of arterial stiffness, was lower in that group by an adjusted 1.18 m/s. Flow-mediated dilation, a measure of how blood vessels respond to increased blood flow, also improved compared with placebo.
Blood tests showed no significant changes in cholesterol or other blood lipids, according to the report. Researchers said the estimated 10-year cardiovascular risk decreased modestly, largely reflecting the blood-pressure difference. That estimate is not the same as observing fewer cardiovascular events, and the trial was not designed to measure such outcomes.
What the Vascular Changes Can Show
The results suggest that a supplement combining vitamins, minerals, amino acids and plant-derived bioactive ingredients may affect several measures associated with vascular health. The measures capture different aspects of blood vessel function and are linked to cardiovascular risk, but they are surrogate markers: changes in them do not by themselves prove a reduction in illness or death.
The reported blood-pressure difference may help frame the scale of the finding, but it needs careful interpretation. The researchers noted that previous large studies have associated a sustained 5 mmHg reduction in systolic blood pressure with an approximately 10% reduction in major cardiovascular events. That comparison concerns reductions sustained over time in other research; the current trial did not track clinical events and cannot show that its participants experienced such a risk reduction.
Products Worth Considering
Oura Ring 5 Smart Ring – Stealth, Size 11
Fitbit Charge 6 Fitness Tracker – Obsidian/Black
Therabody Theragun Prime 6th Generation Deep Tissue Massage Gun, Navy
As an affiliate, we earn on qualifying purchases.
How Researchers Tested the Formula
The study, titled “Acute and 6-month vascular effects of a multi-component nutritional supplement: a randomized controlled trial,” was published in European Heart Journal Open in 2026. The research team examined whether targeting several biological processes associated with aging at once could influence cardiovascular biomarkers. NOVOS Core was developed around that multi-process approach; the trial tested the formulated product, not each ingredient separately.
Professor Christian Heiss, a University of Surrey professor of cardiovascular medicine, said the team chose established markers such as blood pressure and cholesterol as an initial step rather than testing clinical outcomes. He described the observed changes as favorable, while calling for larger studies to examine how they arise and whether they translate into longer-term health benefits.
“We now need larger studies to understand the mechanisms involved and, importantly, whether these changes translate into longer-term health benefits.”
— Christian Heiss, professor of cardiovascular medicine at the University of Surrey
Limits of the Trial Findings
The trial was small, with 61 participants, and lasted six months. The supplied report does not establish whether the findings apply to a broader population, how long any changes persist, or whether they reduce cardiovascular events. It also does not provide enough detail here to assess the participants’ full characteristics, the size of all effects beyond the reported between-group differences, or whether any effects varied among subgroups.
The early response observed one hour after the first dose does not show that an acute change will continue with long-term use. Nor does the absence of significant lipid changes explain the biological mechanisms behind the other findings. The study tested a combination, so the results do not identify which ingredients, if any, drove the changes. Clinical benefit and long-term safety remain unestablished by the information reported.
Larger Trials Must Test Outcomes
The researchers say larger studies are needed to investigate the mechanisms behind the measured changes and determine whether they produce longer-term health benefits. A next stage would need to assess whether the biomarker differences persist and whether they correspond to clinically meaningful outcomes, while also providing enough participants and follow-up to evaluate the results more reliably.
The published report does not specify a planned follow-up trial or its timetable. Until such evidence is available, the findings should be understood as an early clinical study of vascular markers—not proof that NOVOS Core prevents cardiovascular disease.
Key Questions
What did the trial find?
Compared with placebo, participants taking NOVOS Core had improved endothelial function, arterial stiffness and systolic blood pressure after six months. Researchers also reported some changes one hour after the first dose.
How many people took part?
The trial enrolled 61 participants: 33 received the supplement and 28 received a placebo. Both groups were assigned to take their product once daily for six months.
Does the study show that the supplement prevents heart attacks or strokes?
No. The study measured cardiovascular biomarkers and was not designed to assess clinical outcomes such as heart attacks or strokes. Whether the measured changes translate into fewer events remains unknown.
Did the supplement change cholesterol?
The report says blood tests showed no significant changes in cholesterol or other blood lipids. Researchers said the observed vascular-marker changes were not explained by lipid lowering.
What research is needed next?
The researchers called for larger studies to examine how the changes occur and whether they persist or lead to longer-term health benefits. The supplied report does not name a planned next trial or publication date.
Source: news-medical.net
